Chronic stress can lead to the development of anxiety and mood disorders. Thus, novel therapies for preventing adverse effects of stress are vitally important. Recently, the protein tyrosine phosphatase PTP1B was identified as a novel regulator of stress-induced anxiety. This opens up exciting opportunities to exploit PTP1B inhibitors as anxiolytics.
Keywords: anxiolytic therapy; endocannabinoid signaling; glutamate receptor; protein tyrosine phosphatase PTP1B; stress-induced anxiety; trodusquemine/MSI-1436.
Copyright © 2015 Elsevier Ltd. All rights reserved.